Publications

Bachl S, Ching C, Talbot A, Forget A, Kale N, Kochendoerfer C, Nyberg WA, Li Z, Chen PA, Kennedy PH, Liu Q, Muldoon JJ, Liu C, Cusing G, Arang N, Krogan NJ, Allen GM, Marson A, Dodgson SE, Eyquem J, Carnevale J. Disruption of the CRL5 ubiquitin ligase complex enhances engineered T-cell persistence under chronic tumor antigen exposure. Cancer immunology research. 2026. PMID: 42878665

Kim J, Correy GJ, Hall BW, Rachman MM, Mailhot O, Togo T, Gonciarz RL, Jaishankar P, Neitz RJ, Hantz ER, Doruk YU, Stevens MGV, Diolaiti ME, Reid R, Gopalkrishnan S, Krogan NJ, Renslo AR, Ashworth A, Shoichet BK, Fraser JS. Large-scale prospective evaluation of co-folding across hundreds of Mac1-ligand complexes and three virtual screens. eLife. 2026. PMID: 42862171

Grivas P, Agarwal PK, Al-Ahmadie H, Friedlander T, Geynisman DM, Lotan Y, Morgans AK, Bianco FJ, Chandana S, Fang B, Large M, Meeks JJ. Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study. Targeted oncology. 2026. PMID: 42827221

Roy S, Armstrong AJ, Agarwal N, McKay RR, Jia AY, Lichtman-Mikol S, Barata PC, Garcia JA, Brown JR, Mumgandi Y, Basourakos SP, Sheng IY, Kishan AU, Zaorsky NG, Shoag JE, Morgan SC, Wallis CJD, Sun Y, Small EJ, Saad F, Shore ND, Spratt DE. External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial. Cancer. 2026. PMID: 42791604

Mayer EL, Tolaney SM, Martín M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Pérez-Moreno PD, Rugo HS, evERA Breast Cancer Investigators. Giredestrant plus Everolimus in Advanced Breast Cancer. The New England journal of medicine. 2026. PMID: 42814929

Balcar L, Brunetti L, Pomej K, Kreuter A, Maria Fulgenzi CA, Adnan A, Meischl T, D'Alessio A, Manfredi G, Chon HJ, Nishida N, Lee PC, Ang C, Krall A, Ben Khaled N, Stefanini B, Pressiani T, Eid JR, Saeed A, Parisi A, Huang YH, Arvind A, Vivaldi C, Salani F, Masi G, Röhlen N, Vogel A, Schulze K, von Felden J, Silletta M, Trauner M, Rapposelli IG, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Ulahannan SV, Andanamala H, Casadei-Gardini A, Bolnykh I, Mouri S, Roux C, Kaseb A, Rimassa L, Kang B, Celsa C, Li M, Pirisi M, Cammà C, Cabibbo G, Alimenti E, Iavarone M, Lombardi P, Kelley RK, Fortuny M, Reig M, Dalbeni A, Toyoda H, Hsu WF, Lin CY, Lin PT, Scheiner B, Allaire M, Pinato DJ, Pinter M. Prognostic role of the Child-Turcotte-Pugh classification and ALBI grade in patients without cirrhosis and hepatocellular carcinoma. JHEP reports : innovation in hepatology. 2026. PMID: 42815636

Visani L, Becherini C, Kubeczko M, Caini S, Alkner S, Saura C, Starzer AM, Boersma LJ, de Azambuja E, Harbeck N, Stobart H, Spanic T, Coles CE, Cortés J, Curigliano G, Isacke CM, Jackson SP, Jones CM, Kaidar-Person O, Lambertini M, Marangoni E, Morandi A, Offersen B, Paluch-Shimon S, Rugo H, Livi L, Poortmans P, Meattini I, Florence 2026 International Consensus Investigators. Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2026. PMID: 42815776

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic A, Huppert L, Quintal L, Melisko M, Majure M, Chien J, Lechner M, Idossa D, Blaes A, McCann K, Rugo HS, Mortimer J. Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study. Breast (Edinburgh, Scotland). 2026. PMID: 42815081

Fidelman N, Chan K, Keenan BP, Oh DY, Tucker K, Chumber A, Benson C, Cheung A, Zhang L, Bergsland EK, Fong L, Hope TA. Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42803639

Roudsari H, Dhaliwal G, Jagannath AD, Baik AH, Brondfield S. Old disease, new twist. Journal of hospital medicine. 2026. PMID: 42806674

Schinke C, Rodríguez-Otero P, van de Donk NWCJ, Lipe B, Lavi N, Rasche L, Cortes-Selva D, Masterson T, Khedkar S, Tolbert J, Kane C, Saber I, Heuck C, Chari A. Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma. Future oncology (London, England). 2026. PMID: 42803498

Ang KK, Lipof J, Kumar A, Mikkilineni L, Chung A, Arora S, Sayre P, Wolf J, Chari A, Martin T, Pan D. Managing Novel CAR T-Cell Toxicities in Multiple Myeloma. Cancer journal (Sudbury, Mass.). 2026. PMID: 42809699

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026. PMID: 42785981

Desai P, Pawlowska N, Mileti CJ, Worley DR, Wheeler R, Rairkar M, Thomas S, Munster PN. Development of prostate-selective, sustained-release anti-androgen implants for prostate cancer treatment. International journal of pharmaceutics. 2026. PMID: 42772704

Amaral A, DePaula Oliveira L, Dairo O, Villanueva-Pachas CR, Feng K, Woo J, Lu J, Beebe-Dimmer JL, Thrift AP, Wu XC, Stroup A, Shrestha A, Gomez SL, Pollock S, Yacoub R, Ward KC, Joshu C, Huang F, Hamilton AS, Haiman CA, Lotan TL. Optimizing DNA Extraction from Archival Prostate Biopsy Samples. Laboratory investigation; a journal of technical methods and pathology. 2026. PMID: 42767427

Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz A, Kelley RK. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. JHEP reports : innovation in hepatology. 2026. PMID: 42762856

Licata L, Mariani M, Chiavassa A, Partridge AH, Zanibelli C, Jhaveri K, Kalinsky K, Patanè F, Criscitiello C, Lambertini M, Rugo HS, Naldini MM, Notini G, Viale G, Pusztai L, Bianchini G. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2026. PMID: 42754095

Xu X, Mailhot O, Correy GJ, Huang XP, Braz JM, Shi D, Srinivasan K, Zielinski K, Holota Y, Kuziv Y, Iliopoulos-Tsoutsouvas C, Levinzon ND, Doruk YU, Rachman MM, Diolaiti ME, Stevens MGV, Liu F, Holland KL, Hübner H, Wang J, Wu Y, Ashworth A, Makriyannis A, Zhang Y, Moroz YS, Gmeiner P, Abel R, Manglik A, Basbaum AI, Roth BL, Fraser JS, Shoichet BK. Development of a random background to understand ligand optimization. Nature. 2026. PMID: 42749805

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin Y, Ko M, Sayar E, Patton RD, Kollath L, Meis A, Lindergren S, Ji N, Ali K, Venkatesh H, Wladyka CL, McDeed AP, Mills CB, Vashisth M, Kim JY, Nadal R, Hawley JE, Yezefski TA, Psutka SP, Gore JL, Lin DW, Nelson PS, Cheng HH, Schweizer MT, Fong L, Lee JK, Yu EY, Corey E, Morrissey C, Grivas P, Montgomery RB, Wright JL, Haffner MC, Vakar-Lopez F, Mian OY, Lam HM, Hsieh AC, Ha G. Evolution and heterogeneity of lethal metastatic bladder cancer subtypes. Nature. 2026. PMID: 42749807

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH. Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urologic oncology. 2026. PMID: 42731937